A monthly column devoted to IP curiosities and controversies, named in honour of John of Utynam - who received the world's first recorded patent in 1449
The drug that dare not speak its name
Utynam was pleased to receive a piece of news from a Chinese
law firm about Pfizer's recent victory in a Beijing court over
a patent related to its anti-impotence drug Viagra.
In an email accompanying a press release prepared by
Peksung, which advised Pfizer in its long-running dispute with
a group of Chinese companies over the patent, the sender
informed Utynam that "a decision was made today by Beijing
Higher Court regarding the Chinese patent on Pfizer's popular
Utynam thought little more of Peksung's enigmatic refusal to
name its client's blockbuster drug until he sent a reply
thanking the firm for its timely update on developments in the
Viagra case. The email bounced back having been rejected by the
firm's electronic gatekeepers for containing a banned
Utynam is intrigued to know how Pfizer's in-house...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.